Pharma Criticizes Bioethics
Vienna - Oliver Huber, General Secretary of the Austrian industry association Pharmig, criticized the recent sharp increase in fees for the work of the ethics commissions for clinical trials. As a direct result of the new Medicines Law (AMG) in force since May 1, fees have almost tripled. Until recently a pharmaceutical company in Austria paid some Euro1,500. This has risen to Euro4,000 for the Lead Ethics Commission alone plus Euro700 for any further evaluation centre. “SME will not be able to afford clinical trials in Austria any longer. Should the present situation prevail pharmaceutical companies will prefer to go abroad, where clinical trials are much more economical,” forecasts Huber. In Germany companies pay around Euro1,500, in Great Britain Euro1,000, and in France Euro1,450.